KRAS is the most frequently mutated oncogene in solid tumors in general, and in lung tumors in particular. There are more patients whose lung tumors are driven by KRAS mutations than by ALK, Ros, Ret and TRK alterations. Combined.
By combining synthetic biology and RNA therapy, the team at startup Strand Therapeutics Inc. hopes to make mRNA therapy more effective. Strand recently announced an immuno-oncology deal with Beigene Ltd. that netted the company $5 million to begin with and could end up being worth more than $250 million. Beyond immuno-oncology, the company’s basic technology could be broadly useful for both mRNA- and cell-based therapies.
Keeping you up to date on recent developments in neurology, including: Genetic analysis of symptoms yields new insights into PTSD; AI used to predict schizophrenia in relatives of patients; Growth factors linked to lysosomes, Parkinson’s risk; Study links ALS gene to tumor suppressor, transcription changes.
Keeping you up to date on recent developments in diagnostics, including: Diagnosing myotonia; Lumbar spine MRI interpretation; Gray matter damage in MS starts at synapses.
Keeping you up to date on recent developments in oncology, including: Hypoxia a potential marker for recurrent glioblastoma; SCLC subtypes have specific vulnerabilities; Few-shot learning may speed up drug development; New research may move up breast cancer diagnosis.
Keeping you up to date on recent developments in neurology, including: Personalized neuromodulation technique developed for obsessive-compulsive behavior; Improving pain research with new sensory neuron model; Tau end run prevents memory deficits, but not inflammation; Presenilin mutations affect neuronal stem cells.
